Open Research Studies at the Penn Memory Center


The Generation Study is a phase II/III clinical trial to test whether the drug CAD106 prevents Alzheimer’s disease. Cognitively normal individuals 60-75 years of age with an increased genetic risk of developing Alzheimer’s disease may be eligible. CAD106 is an investigational drug and is not FDA-approved.

Eligible participants will have two copies of the APOE 4 gene. If you do not know your genotype and are interested in learning more about how you may be eligible for the study, please visit the GeneMatch Study website at GeneMatch is a research program of the Alzheimer’s Prevention Registry for people interested in participating in The Generation Study and other Alzheimer’s research studies based on their genetic information.


The Biogen study is a Phase II clinical research study of the drug aducanumab for individuals age 50-85 with early Alzheimer’s disease, including mild cognitive impairment.

Aducanumab is a human antibody that recognizes some forms of beta-amyloid. The primary objective of the study is to evaluate the efficacy of aducanumab in slowing cognitive and functional impairment. This drug is not FDA-approved and is investigational.

Click here for a one-page handout on Biogen.


The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 for short), is a clinical research study for older individuals who may be at risk for Alzheimer’s disease (AD). The A4 study is investigating a drug intervention, solanezumab, and Individuals 65-85 years of age with normal cognition may be eligible. The study requires infusion visits every four weeks, for a total of 42 infusion visits over three consecutive years.


Download a one-page overview of this study including contact information

Welcome to Penn Memory Center


Aging and Cognition: Maintaining Economic Security in Later Life

On May 9 and 10, the World Economic Forum’s Global Agenda Council on Ageing (WEF GAC) and the University of Pennsylvania’s Healthy Brain Research Center were pleased to host “Aging and Cognition: Maintaining Economic Security in Later Life,” the fourth and final symposium in a series presented by the WEF GAC.

The symposia intended to increase action and impact on innovative approaches in the financial services sector to overcome limitations of age-related cognitive decline. Outcomes of each symposium will be shared through comprehensive reports, feedback, and recommended actions for engagement.

Click here to learn more about each symposia and watch videos of most Philadelphia presentations.

News and Events

  The first goal of the U.S. national Alzheimer’s plan is that, by 2025, researchers will discover ways to diagnose
Read More

  Legendary local sportswriter Bill Lyon has a long list of titles — journalist, columnist emeritus, Pulitzer Prize nominee —
Read More

  The American health care system is out of date and only recently has taken on a national goal to
Read More

  As more Alzheimer’s disease (AD) prevention trials require participants to undergo genetic or biomarker testing in order to enroll,
Read More

The Memory Café returns Friday, October 7, 2016 with local comedian Leah Lawler, who will conduct some long-form improv comedy lessons to
Read More

Penn Memory Center in the Community

Click here to find out about the important work the Penn Memory Center is doing in the Philadelphia community.

 PMC in community

What does it mean to be a caregiver?

Click here to listen to the stories of caregivers from the PMC community.

I am a Caregiver


The University of Pennsylvania Prevention Research Center

The University of Pennsylvania Prevention Research Center seeks to advance public health goals, and serves as a hub for interdisciplinary chronic disease prevention research, training, and dissemination at the University of Pennsylvania.

Penn Memory Center's Jason Karlawish, MD, leads one of the PRC's Special Interest Projects - Alzheimer's/Dementia Assessment Messaging - and one of the SIP's Collaborating Networks - The Healthy Brain Research Center.

To read more about the PRC's work, visit their website at